Aducanumab: Dr Terry Quinn explains approval of new Alzheimer’s disease drug
SDRC Executive Committee member, Dr Terry Quinn, Terry takes us through all the important facts behind the recent announcement by the FDA in the US to approve aducanumab for the treatment of Alzheimer’s disease.
For comprehensive coverage of all the important questions on this drug, visit the Brain Health Scotland website
Meet the rest of the Executive Committee
Our SDRC Executive Committee are researchers and contain representation from different career stages, institutions and research disciplines. They are active in supporting the work of the SDRC and dementia and brain health research more widely